Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Received 22 June 2008; received in revised form 14 August 2008; accepted 14 August 2008. published online 20 October 2008.
Objective
To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients.
Design
Systematic review and meta-analysis.
Setting
Academic Department of Obstetrics and Gynecology in Italy.
Patient(s)
Women affected by PCOS receiving pregestational metformin.
Intervention(s)
Systematic review of randomized controlled trials (RCTs) published up to June 2008 and subsequent meta-analysis.
Main Outcome Measure(s)
Abortion rate.
Result(s)
Seventeen RCTs were included in the final analysis. Overall, no effect of the metformin administration was detected on the abortion risk. No statistically significant effect of metformin on the abortion risk was observed in any comparison when subgrouping the RCTs according to received treatment.
Conclusion(s)
Metformin has no effect on the abortion risk in PCOS patients when administered before pregnancy.
aDepartment of Gynecology and Obstetrics, University “Magna Graecia” of Catanzaro, Italy
bEndocrinology, Faculty of Exercise Sciences, University “Parthenope,” Naples, Italy
Reprint requests: Stefano Palomba, M.D., Department of Gynecology and Obstetrics, University “Magna Graecia” of Catanzaro, Via Tommaso Campanella 182/1, 88100 Catanzaro, Italy (FAX: +390961961820).
S.P. has nothing to disclose. A.F. has nothing to disclose. F.O. has nothing to disclose. F.Z. has nothing to disclose.
ABSTRACT